Rothschild is one of the few investment banks that can truly lay claim to being just as focused on the mid-market as it is on large-cap deals. With 23 deal credits to its name so far this year, Rothschild has worked on more than double the number of mid-market deals in Europe than its nearest competitor Credit Suisse, according to Dealogic.

Rothschild is also ranked first by value, with a combined total of $6.1bn (€4.6bn). Highlights include advising private equity group Bridgepoint Capital on its $685m acquisition of care home group Care UK and advising Swiss pharma group Mepha Pharma on its $586m acquisition by US rival Cephalon.